NasdaqHealth CareHealth Care SuppliesS&P SmallCap 600
$172.11
+4.46 (+2.66%)
Close of Nov 06, 2026 · end-of-day data
ICUI 8-K filings in 2025
Every material Form 8-K ICU Medical filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ICU Medical reported third quarter 2025 revenue of $537.0 million, down from $589.1 million a year earlier, after disposing of its IV Solutions business on May 1, 2025. Its GAAP net loss narrowed to $(3.4) million, or $(0.14) per diluted share, from $(33.0) million, and it raised its full-year 2025 adjusted EBITDA and adjusted EPS guidance. Shareholders get higher profit measures alongside lower sales.
Q3 2025 revenue was $537.0 million versus $589.1 million in Q3 2024; Vital Care revenue fell to $78.0 million from $164.5 million.
Q3 2025 GAAP net loss was $(3.4) million, or $(0.14) per diluted share, compared with $(33.0) million, or $(1.35), a year earlier.
Q3 2025 adjusted diluted EPS was $2.03 versus $1.59; adjusted EBITDA was $105.9 million versus $94.8 million.
Fiscal 2025 adjusted EPS guidance was raised to $7.35–$7.65 from $6.85–$7.15, and adjusted EBITDA guidance to $395 million–$405 million from $380 million–$390 million.
ICU Medical reported second quarter 2025 revenue of $548.9 million, down from $596.5 million a year earlier, and GAAP net income of $35.3 million, or $1.43 per diluted share, which included a $41.8 million gain on sale of a business. The company also narrowed its 2025 adjusted EBITDA guidance to $380 million to $390 million from $380 million to $405 million, and adjusted diluted EPS guidance to $6.85 to $7.15 from $6.55 to $7.25, so shareholders face lower revenue and a lower top end for adjusted EBITDA guidance despite higher reported profit.
Q2 2025 revenue was $548.9 million versus $596.5 million in Q2 2024; Vital Care revenue fell to $108.0 million from $171.0 million.
GAAP net income was $35.3 million, or $1.43 per diluted share, versus a net loss of $21.4 million, or $0.88 per share, a year earlier.
Adjusted diluted EPS was $2.10 versus $1.56; adjusted EBITDA was $100.3 million versus $91.3 million.
Full-year 2025 adjusted EBITDA guidance high end lowered to $390 million from $405 million; the low end stayed at $380 million.
At its annual meeting on May 13, 2025, ICU Medical stockholders approved a third amendment to the 2011 Stock Incentive Plan, raising the total shares available for issuance to 8,515,510 and the incentive stock option limit by the same 2,150,000 shares. Stockholders also elected all seven director nominees and ratified Deloitte & Touche LLP as the independent auditor for fiscal 2025.
Plan amendment adds 2,150,000 shares, bringing the aggregate to 8,515,510 shares of common stock; the incentive stock option limit rises by the same amount.
All seven director nominees were elected, including Vivek Jain with 21,022,893 votes for and 550,209 withheld.
Advisory simple majority voting proposal passed with 18,429,634 votes for and 3,094,805 against.
Deloitte & Touche LLP was ratified for the fiscal year ending December 31, 2025, with 22,516,651 votes for and 1,165,480 against.
ICU Medical reported first quarter 2025 revenue of $604.7 million, up from $566.7 million a year earlier, and a GAAP net loss of $15.5 million, or $0.63 per diluted share, compared with a $39.5 million loss, or $1.63 per share, in the first quarter of 2024. Adjusted diluted earnings per share rose to $1.72 from $0.96, and CEO Vivek Jain said results were generally in line with company expectations.
Revenue was $604.7 million, compared with $566.7 million in Q1 2024.
GAAP net loss was $15.5 million, or $(0.63) per diluted share, versus $39.5 million, or $(1.63) per share, a year earlier.
Adjusted diluted EPS was $1.72, compared with $0.96 in Q1 2024; adjusted EBITDA was $99.4 million, versus $78.8 million.
GAAP gross margin was 35%, compared with 33% in the prior-year quarter.
ICU Medical reported fourth quarter 2024 revenue of $629.8 million, up from $587.9 million a year earlier, and adjusted diluted EPS of $2.11 versus $1.57. GAAP net loss widened to $23.8 million, or $(0.97) per share, from $17.1 million, or $(0.71) per share, a year earlier. The company also gave fiscal 2025 guidance for GAAP net loss of $(45) million to $(28) million and adjusted EPS of $6.55 to $7.25, excluding a pending IV Solutions joint venture.
Q4 2024 revenue was $629.8 million, versus $587.9 million in Q4 2023; GAAP gross margin was 36.1%, versus 29.2%.
Q4 2024 adjusted EBITDA was $105.5 million, versus $86.3 million; GAAP net loss was $(23.8) million, or $(0.97) per diluted share.
FY2025 guidance: GAAP net loss of $(45) million to $(28) million; adjusted EBITDA of $395 million to $425 million, excluding the IV Solutions joint venture.
The IV Solutions joint venture is expected to close in Q2 2025 and, if so, reduce 2025 adjusted EBITDA guidance by $15 million to $20 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ICU Medical filing is on SEC EDGAR ↗. 8-K briefs of other companies →